LISATA THERAPEUTICS INC. - COMMON STOCK

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

05 Feb 2025 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

23 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

22 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

15 Jan 2025 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

10 Dec 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

03 Dec 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

06 Nov 2024 09:23:21 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

06 Nov 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

31 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

28 Oct 2024 08:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

03 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

17 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

09 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

12 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024

05 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

18 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

16 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

10 Jul 2024 08:00:00 By Nasdaq GlobeNewswire